Another EB patient included in cancer study at EB House Austria
The multicentre clinical phase 1/2 trial with the active substance "Rigosertib" is the first clinical trial of a so-called "targeted" cancer therapy for RDEB patients.
One patient has already been treated in Salzburg. Now the second patient is already receiving the potentially life-saving therapy. Together with DEBRA Austria, the team at the study centre has joined forced to ensure that a British patient receives the treatment in Salzburg. As the study currently only includes patients at EB House Austria in Salzburg and at Thomas Jefferson University in the USA, this step was necessary.
The patient is expected to spend the entire treatment period (1 year) in Salzburg and will be visited by relatives on an ongoing basis.
We wish the patient all the best.
Further open studies in the EB House can be found on the EB House website: Current clinical studies - EB Haus Austria
Other ongoing and completed clinical trials can be found in our clinical trails database.